Skip to main content

Table 3 Median OS and PFS for 39 SMZL patients separated by treatment modality

From: Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center

Treatment

Median OS (CI 95%)

Median PFS (CI 95%)

Rituximab

5.9 year (3.8-7.9)

6.0 year (4.3-7.7)

Splenectomy

13.9 year (8.4-19.4)

10.9 year (5.7-16.2)

Chemotherapy

13.5 year (5.8-21.2)

15.1 year (10.3-19.9)

p-value

0.565

0.530

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us